Therapeutic applications of mesenchymal stroma cells in pediatric diseases: Current aspects and future perspectives

Medical Science Monitor

Volumn 17, Issue 11, 2011, Pages 233-239

  Habi, Hamid S ^a   Halawa, Taher F ^a   Atta, Hazem M ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Bone marrow mesenchymal stem cells; Hematolocical diseases; Tissue regeneration

Indexed keywords

ADJUVANT THERAPY; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; BLADDER RECONSTRUCTION; CARDIOVASCULAR DISEASE; CHILD; CHILDHOOD DISEASE; CONVALESCENCE; DISEASE CONTROL; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; LUNG DISEASE; MEDLINE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESH HEADING; MUSCULOSKELETAL DISEASE; PEDIATRIC SURGERY; RISK ASSESSMENT;

ANEMIA, APLASTIC; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; GRAFT VS HOST DISEASE; HUMANS; LUNG DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MUSCULOSKELETAL DISEASES; PEDIATRICS; REGENERATIVE MEDICINE;

EID: 80355149226     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Liu ZJ, Zhuge Y, Velazquez OC: Traffcking and differentiation of mes-enchymal stem cells. J Cell Biochem, 2009; 106: 984-91
2. Friedman SL: Liver fibrosis - from bench to bedside. J Hepatol, 2003; 38(Suppl.1), S38-53
3. Iredale JP: Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ, 2003; 327: 143-47
4. Lee DS et al: Factors affecting graft survival after living donor liver transplantation. Transplant Proc, 2006; 36: 2255-56
5. Piersma AH et al: Characterization of fibroblastic stromal cells from murine bone marrow. Exp Hematol, 1985; 13: 237-43
6. Owen SJ, Watson CM, Davison AN: Multiple sclerosis: a T-cell disease? Lancet, 1988; 2: 801
7. Woodbury D, Schwarz EJ, Prockop DJ, Black IB: Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res, 2000; 61: 364-70
8. Colter DC, Class R, DiGirolamo CM, Prockop DJ: Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci USA, 2000; 97: 3213-18
9. Bruder SP, Jaiswal N, Haynesworth SE: Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem, 1997; 64: 278-94
10. Zhao DC et al: Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World J Gastroenterol, 2005; 11: 3431-40
11. Wakitani S, Saito T, Caplan AI: Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve, 1995; 18: 1417-26
12. Bonfeld TL, Caplan AI: Adult mesenchymal stem cells: an innovative therapeutic for lung diseases. Discov Med, 2010; 9: 337-45
13. Dominici M et al: Minimal criteria for defning multipotent mesenchy-mal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 2006; 8: 315-17
14. Abdallah BM et al: Dlk1/FA1 regulates the function of human bone marrow mesenchymal stem cells by modulating gene expression of pro-infammatory cytokines and immune response-related factors. J Biol Chem, 2007; 282: 7339-51
15. Le Blanc K, Ringden O: Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med, 2007; 262: 509-25
16. Bai L, Caplan A, Lennon D, Miller RH: Human mesenchymal stem cells signals regulate neural stem cell fate. Neurochem Res, 2007; 32: 353-62
17. Maciejewski JP, Risitano A: Hematopoietic stem cells in aplastic anemia. Arch Med Res, 2010; 34: 520-27
18. Isaikina Y, Shman T: Influence of mesenchymal stem cells derived from bone marrow of children with oncohematological diseases on proliferation and self-renewal of hematopoietic progenitor cells in vitro. Exp Oncol, 2008; 30: 121-28
19. Muller I et al: Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis, 2008; 40: 25-32
20. Fang B, Song Y, Zhao RC et al: Using human adipose tissue-derived mes-enchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. Transplant Proc, 2007; 39: 1710-13
21. + cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience. Neoplasma, 2008; 55: 428-36
22. Prasad VK et al: Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant, 2011; 17: 534-41
23. Lucchini G et al: Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pedi-atric population. Biol Blood Marrow Transplant, 2010; 16: 1293-301
24. Wu KH et al: Effective Treatment of Severe Steroid-Resistant Acute Graft-Versus-Host Disease With Umbilical Cord-Derived Mesenchymal Stem Cells. Transplantation 2011; 91(12): 1412-16
25. Wang LL, Gao C, Chen BA: [Research progress on mechanism of MDS transformation into AML]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 19: 254-59 [in Chinese]
26. Ringden O, Le Blanc K: Mesenchymal stem cells combined with cyclo-sporine inhibits cytotoxic T cells. Biol Blood Marrow Transplant, 2006; 12: 693-94
27. Lazarus HM et al: Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in he-matologic malignancy patients. Biol Blood Marrow Transplant, 2005; 11: 389-98
28. Polchert D et al: IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol, 2008; 38: 1745-55
29. Le Blanc K et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 2008; 371: 1579-86
30. Ortin M, Sierra J: Use of mesenchymal stem cells as treatment for graft-versus-host disease: current knowledge and controversies. Immunotherapy, 2011; 3: 701-4
31. Pozzobon M, Ghionzoli M, De Coppi P: ES, iPS, MSC, and AFS cells. Stem cells exploitation for Pediatric Surgery: current research and perspective. Pediatr Surg Int, 2010; 26: 3-10
32. Zeinaloo A et al: Intracoronary administration of autologous mesen-chymal stem cells in a critically ill patient with dilated cardiomyopathy. Pediatr Transplant, 2010
33. Abdel Aziz MT et al: Effect of bone marrow-derived mesenchymal stem cells on cardiovascular complications in diabetic rats. Med Sci Monit, 2008; 14(11), BR249-BR255
34. Kwan MD, Slater BJ, Wan DC, Longaker MT: Cell-based therapies for skeletal regenerative medicine. Hum Mol Genet, 2008; 17: R93-98
35. Salvade A et al: Characterization of platelet lysate cultured mesenchy-mal stromal cells and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. Tissue Eng Part C Methods, 2010; 16: 201-14
36. Haleem AM et al: The Clinical Use of Human Culture-Expanded Autologous Bone Marrow Mesenchymal Stem Cells Transplanted on Platelet-Rich Fibrin Glue in the Treatment of Articular Cartilage Defects: A Pilot Study and Preliminary Results. Cartilage, 2010; 1: 253-61
37. Traggiai E et al: Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells, 2008; 26: 562-69
38. Bruscia EM et al: Macrophages directly contribute to the exaggerated inflammatory response in cystic fbrosis transmembrane conductance regulator-/- mice. Am J Respir Cell Mol Biol, 2009; 40: 295-304
39. Weiss DJ et al: Adult stem cells, lung biology, and lung disease. NHLBI/ Cystic Fibrosis Foundation Workshop. Proc Am Thorac Soc, 2006; 3: 193-207
40. Atala A: Tissue engineering of human bladder. Br Med Bull, 97; 81-104
41. Zhu WD et al: Bladder reconstruction with adipose-derived stem cell-seeded bladder acellular matrix grafts improve morphology composition. World J Urol, 2010; 28: 493-98
42. Atala A: Regenerative medicine and tissue engineering in urology. Urol Clin North Am, 2009; 36: 199-209, viii-ix
43. Kelly C, Flatt CC, McClenaghan NH: Stem cell-based approaches for the treatment of diabetes. Stem Cells Int, 2011: 424-986
44. Ryan EA, Imes S, Wallace C: Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care, 2004; 27: 1028-32
45. Cohen ND, Shaw JE: Diabetes: advances in treatment. Intern Med, 2007; 37: 383-88
46. Voltarelli JC et al: Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA, 2007; 297: 1568-76
47. Couri CE et al: C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA, 2009; 301: 1573-79
48. Silva Dda F et al: [Hemophagocytic Syndrome: a clinical presentation of systemic lupus erythematosus]. Acta Reumatol Port, 2008; 33: 91-97